Abstract
Introduction
Intanza® 9 μg (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as a vaccination for adults aged 18 to 59 years old, as of the 2010 southern hemisphere influenza season.
Methods
This study was designed to assess the acceptability of intradermal vaccination with Intanza 9 μg in routine clinical practice by adult vaccinees and their prescribers. Prescribers and healthy adults 18 to 59 years old in Australia and Argentina who had elected to be vaccinated with Intanza 9 μg during the 2010 southern hemisphere influenza season were recruited to complete surveys about their opinions of influenza vaccination and acceptance of the intradermal vaccination.
Results
1402 vaccinees and 30 prescribers in Australia, and 264 vaccinees and 16 prescribers in Argentina responded to surveys. In both countries, 98% of vaccinees were satisfied or very satisfied with Intanza 9 μg. The main reasons for satisfaction were that the injection was considered minimally painful and that the vaccination was quickly administered. Most (95%) vaccinees reported that they would prefer to receive the same vaccination next year. Furthermore, 85% of prescribers were satisfied or very satisfied with the intradermal vaccine.
Conclusion
Intradermal vaccination for seasonal influenza using Intanza 9 μg is well accepted both by adult vaccinees and prescribers. By providing an additional, well-accepted method, Intanza 9 μg might help increase seasonal influenza vaccination rates in adults.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc. 2010;85:257–273.
Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med. 1982;142:85–89.
Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58:446–458.
Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369–393.
Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25:8833–8842.
Atmar RL, Patel SM, Keitel WA. Intanza intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010;9:1399–1409.
Arnou R, Icardi G, De Decker M, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.
European Medicines Agency. Assessment report for Intanza Agency; 2009.
Reygrobellet C, Viala-Danten M, Meunier J, et al. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from phase 3 clinical trials. Hum Vaccin. 2010;6:336–345.
Jabbal-Gill I. Nasal vaccine innovation. J Drug Target. 2010;18:771–786.
Kweon MN. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine. 2011;54:1–5.
Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines. 2008;7:1201–1214.
Madjid M, Alfred A, Sahai A, et al. Factors contributing to suboptimal vaccination against influenza: results of a nationwide telephone survey of persons with cardiovascular disease. Tex Heart Inst J. 2009;36:546–552.
Kroneman MW, van Essen GA. Stagnating influenza vaccine coverage rates among highrisk groups in Poland and Sweden in 2003/4 and 2004/5. Euro Surveill. 2007;12:E1–E2.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Eizenberg, P., Booy, R., Naser, N. et al. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv Therapy 28, 640–649 (2011). https://doi.org/10.1007/s12325-011-0042-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-011-0042-0